WO2003093293A3 - Peptide antagonists of tgf-beta family members and therapeutic uses thereof - Google Patents

Peptide antagonists of tgf-beta family members and therapeutic uses thereof Download PDF

Info

Publication number
WO2003093293A3
WO2003093293A3 PCT/US2003/011437 US0311437W WO03093293A3 WO 2003093293 A3 WO2003093293 A3 WO 2003093293A3 US 0311437 W US0311437 W US 0311437W WO 03093293 A3 WO03093293 A3 WO 03093293A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
family members
therapeutic uses
peptide antagonists
beta family
Prior art date
Application number
PCT/US2003/011437
Other languages
French (fr)
Other versions
WO2003093293A2 (en
Inventor
Jung San Huang
Original Assignee
Jung San Huang
Univ Saint Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jung San Huang, Univ Saint Louis filed Critical Jung San Huang
Priority to AU2003234734A priority Critical patent/AU2003234734A1/en
Priority to CA2484994A priority patent/CA2484994C/en
Priority to EP03728390A priority patent/EP1534737A4/en
Publication of WO2003093293A2 publication Critical patent/WO2003093293A2/en
Publication of WO2003093293A3 publication Critical patent/WO2003093293A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention is drawn to methods of using peptide-based antagonists of TGF-beta to facilitate the healing of cutaneous wounds that includes burns, lacerations and scrapes. The administration of peptide TGF-beta antagonists to wounds results in reduced scarring, wound contraction and deposition of extracellular matrix components, and increased rates of re-epithelialiation during wound healing.
PCT/US2003/011437 2002-04-29 2003-04-15 Peptide antagonists of tgf-beta family members and therapeutic uses thereof WO2003093293A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003234734A AU2003234734A1 (en) 2002-04-29 2003-04-15 Peptide antagonists of tgf-beta family members and therapeutic uses thereof
CA2484994A CA2484994C (en) 2002-04-29 2003-04-15 Peptide antagonists of tgf-beta family members and therapeutic uses thereof
EP03728390A EP1534737A4 (en) 2002-04-29 2003-04-15 Peptide antagonists of tgf-beta family members and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13594602A 2002-04-29 2002-04-29
US10/135,946 2002-04-29

Publications (2)

Publication Number Publication Date
WO2003093293A2 WO2003093293A2 (en) 2003-11-13
WO2003093293A3 true WO2003093293A3 (en) 2005-04-07

Family

ID=29399231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011437 WO2003093293A2 (en) 2002-04-29 2003-04-15 Peptide antagonists of tgf-beta family members and therapeutic uses thereof

Country Status (4)

Country Link
EP (1) EP1534737A4 (en)
AU (1) AU2003234734A1 (en)
CA (1) CA2484994C (en)
WO (1) WO2003093293A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
AU2005311098B2 (en) * 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP3181580A1 (en) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
KR100879239B1 (en) * 2007-04-19 2009-01-16 (주)케어젠 Peptide and Its Uses
EP2192904B1 (en) 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
EP3398966A1 (en) 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Methods and compositions for modulating angiogenesis and pericyte composition
ES2337973B8 (en) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. ADENOVIRUS AUXILIARY SELF-INACTIVANTS FOR THE PRODUCTION OF ADENOVIRUS RECOMBINANTS OF HIGH CAPACITY.
ES2330826B1 (en) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. HIGH CAPACITY ADENOVIRUS PACKING SYSTEM.
EP2341913B1 (en) 2008-09-16 2014-11-19 Saint Louis University Method of enhancing tgf-beta signalling
JP5611322B2 (en) * 2009-04-14 2014-10-22 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Peptide having transforming growth factor activity and use thereof
CN102712933A (en) 2009-11-05 2012-10-03 西马生物医学计划公司 Regulated expression systems
WO2012001196A2 (en) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Alphaviral vectors and the uses thereof for heterologous gene expression
EP2407534A1 (en) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
WO2013113755A1 (en) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
ES2523016B1 (en) 2013-05-20 2015-09-09 3P Biopharmaceuticals Alpha-viral vectors and cell lines for the production of recombinant proteins
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
WO2000031135A1 (en) * 1998-11-24 2000-06-02 Instituto Cientifico Y Tecnologico De Navarra, S.A. TGF$G(b)1 INHIBITOR PEPTIDES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
WO2000031135A1 (en) * 1998-11-24 2000-06-02 Instituto Cientifico Y Tecnologico De Navarra, S.A. TGF$G(b)1 INHIBITOR PEPTIDES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1534737A4 *

Also Published As

Publication number Publication date
AU2003234734A8 (en) 2003-11-17
WO2003093293A2 (en) 2003-11-13
CA2484994C (en) 2016-06-14
EP1534737A4 (en) 2007-10-31
EP1534737A2 (en) 2005-06-01
CA2484994A1 (en) 2003-11-13
AU2003234734A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
WO2003093293A3 (en) Peptide antagonists of tgf-beta family members and therapeutic uses thereof
CL2003002353A1 (en) COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
SE0300207D0 (en) New use and composition
WO2003018748A3 (en) Anti-cancer and wound healing compounds
DE60138549D1 (en) TOPICAL GEL DELIVERY SYSTEMS FOR THE TREATMENT OF SKIN DISEASES
TW200605870A (en) Topical methadone compositions and methods for using the same
JP2008526935A5 (en)
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
ATE512163T1 (en) ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
WO2005055945A3 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
NO20062198L (en) Bradykinin B1 receptor antagonists
WO2006126188A3 (en) Cxcr4 antagonists for wound healing and re-epithelialization
CY1108992T1 (en) USE OF HYALURONIC ACID FOR PREPARATION OF COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF ORAL TRAUMATIC DISEASES
WO2006048450A3 (en) Peptides for use in the treating obesity
WO2006048452A3 (en) Peptides for use in treating of obesity
WO2003082196A3 (en) Combination therapy using trefoil peptides
EA200600782A1 (en) THERAPEUTIC APPLICATIONS OF HEMOKIN VARIANTS
TR200102107T2 (en) Tumor necrosis factor antagonists and their use in endometriosis.
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
WO2003022205A3 (en) Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
DE60142632D1 (en) HEALING OF WOUNDS
JP2004532892A5 (en)
IL164822A0 (en) Growth factor delivery system for the healing of wounds and the prevention and disease
WO2003018535A3 (en) Novel aminobenzoephenones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2484994

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003728390

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003728390

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP